Remove Biomarkers Remove Heart Failure Remove Myocardial Infarction
article thumbnail

Clinical significance of NT-proBNP as a predictive biomarker of depressive symptoms in cardiac patients

Frontiers in Cardiovascular Medicine

More than half of the patients presented with heart failure (n=2,234, 55.4%), followed by acute myocardial infarction (n=1,368, 34.0%), coronary artery disease (n=674, 16.7%), and acute coronary syndrome (n=164, 4.1%). Poor ventricular function (26.16.8

article thumbnail

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction

DAIC

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by CellProthera , as well as plans to continue the relationship into Phase III.

article thumbnail

Association between trimethylamine N-oxide and prognosis of patients with myocardial infarction: a meta-analysis

Frontiers in Cardiovascular Medicine

BackgroundTrimethylamine N-oxide (TMAO) has been widely explored and considered as a biomarker for adverse cardiovascular events. Therefore, this meta-analysis aimed to estimate association between TMAO levels and the prognosis of patients with myocardial infarction (MI).MethodsWe were systematically addressed.

article thumbnail

Interrelation between hypoxic liver injury and Killip classification in ST-segment elevation myocardial infarction patients

Frontiers in Cardiovascular Medicine

IntroductionHypoxic liver injury (HLI) and Killip classification are poor prognostic factors in patients with ST-segment elevation myocardial infarction (STEMI). Left ventricular ejection fraction (LVEF) was below 45% in symptomatic, overt heart failure patients (Killip class II, III, and IV).

article thumbnail

Abstract 4139191: ETX-258 - A GalOmic™ siRNA for the Treatment of Heart Failure Following Myocardial Infarction

Circulation

These challenges highlight the need for new therapies that are both safe and effective in targeting the structural remodeling pivotal to disease progression post-myocardial infarction (MI). Current treatments are limited by side effects, poor patient compliance, and the necessity for gradual drug titration.

article thumbnail

S100a8/A9 proteins: critical regulators of inflammation in cardiovascular diseases

Frontiers in Cardiovascular Medicine

This article evaluates the utility of S100A8/A9 protein as a biomarker and therapeutic target for diagnosing cardiovascular diseases, considering its structural features, fundamental biological properties, and its multifaceted influence on cardiovascular conditions including atherosclerosis, myocardial infarction, myocardial ischemia/reperfusion injury, (..)

article thumbnail

Comparison of troponin and natriuretic peptides in Takotsubo syndrome and acute coronary syndrome: a meta-analysis

Open Heart

Objective Takotsubo syndrome (TTS) is an acute heart failure syndrome which resembles acute coronary syndrome (ACS) at presentation. Differentiation requires coronary angiography, but where this does not occur immediately, cardiac biomarkers may provide additional utility. to 0.80; p<0.00001) and 5.8